Biologics And Biosimilars In India: Strengthening India’s Healthcare System

Biologics and biosimilars are increasingly transforming India’s healthcare landscape by improving applications to advanced therapies. Biologics including monoclonal antibodies, vaccines, recombinant proteins and hormones, have revolutionized the treatment of chronic and life-threatening diseases such as cancer, diabetes and autoimmune disorders. However, their high cost limits its use in the larger sector of population. Biosimilars have highly similar and more affordable versions of biologics and viable solutions to cost challenges. India has emerged as a major role player in the global biosimilar market due to its strong pharmaceutical manufacturing capabilities, skilled workers and supportive regulatory environment. The adaptation of biosimilars can significantly reduce healthcare cost and enhance treatment accessibility. There are some challenges while adaptation of biosimilars in treatments, like limited awareness among healthcare providers and efficacy assurance. Addressing these issues through policy reforms, education and a stringent pharmacovigilance system is essential. Strengthening the integration of biologics and biosimilars into India’s healthcare system will not only improve patient outcomes but also position the country as a global leader in affordable biopharmaceutical innovation.